Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Inc.

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio, with a price target of $15.00. According to ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GOSS	$3.60	-0.55%	3.48M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GOSS	$3.60	-0.6%	3.48M
3
4
5
6

GOSS

GOSS

Dividend Overview

Get Gossamer Bio Inc. Data in Excel

Get Gossamer Bio Inc. Data in Excel